PFE - Pfizer-Acquired Seagen's Adcetris Combo Therapy Extends Overall Survival Versus Placebo In Patients With Most Common Type Of Lymphoma | Benzinga
Tuesday, Pfizer Inc (NYSE:PFE) announced that a Phase 3 study of the antibody-drug conjugate Adcetris (brentuximab vedotin) combined with lenalidomide and rituximab for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) showed a statistically significant and clinically meaningful improvement in overall survival (OS) compared to lenalidomide and rituximab plus placebo.
Positive outcomes were also observed in key secondary endpoints, including progression-free survival (PFS) and overall response rate (ORR).
Also Read: Pfizer Shifts Strategic Focus, Pivoting From COVID To Cancer Drugs To Recover Market Value.
The safety ...